Topic: Evusheld

A photo taken on February 8, 2022 shows a box of Evusheld, a drug for antibody therapy developed by pharmaceutical company AstraZeneca for the prevention of COVID-19 in immunocompromised patients at the AstraZeneca facility for biological medicines in Södertälje, south of Stockholm, Sweden. - AstraZenecas new facility in Sweden located in Södertälje was inaugurated last December and is dedicated to the production of next generation biological drugs such as Evusheld, a Covid-19 preventative monoclonal antibody treatment for immunocompromised people. (JONATHAN NACKSTRAND/AFP via Getty Images)

Evusheld is becoming hard to find

Hannah Recht - KFF Health News